Skip to content

About Us
Contact Us
Terms Of Use
Privacy Policy

cell therapy setback

Categories

2seventy bio, cell therapy, Cell & Gene Therapy, layoffs, sickle cell disease, beta-thalassemia, cell therapy setback, 2seventy bio layoffs

Latest News Cell & Gene Therapy Pharma

2seventy Bio slashes 176 jobs and looks for new CEO after cell therapy setback

12 September 2023

Anika Sharma

2seventy bio, the spinoff from bluebird bio, is undergoing significant changes under the leadership of CEO Nick Leschly. The company ...

most recent

More

Alexion Gains Voyager's Preclinical Capsid in $1B Pfizer Handoff

Latest News, Deals, Pharma

Alexion Acquires Voyager’s Preclinical Capsid for Rare Neurological Disease After $1B Pfizer Transfer

Vertex Pharmaceuticals Shifts Strategy After Suspending Phase 2 Lung Therapy

Pharma, Clinical Trials, Latest News

Vertex Halts Phase 2 Lung Therapy, Reevaluates DMD Drug’s Clinical Path

Ventyx Halts TYK2 Inhibitor Following Phase 2 Success

Latest News, Clinical Trials, Pharma

Ventyx Halts TYK2 Inhibitor Despite Phase 2 Success, Stock Plummets 70%

Johnson & Johnson's Ottava Surgical Robot Set for U.S. Clinical Trials

Latest News, Pharma

J&J MedTech Plans US Clinical Trials for Ottava Surgical Robot in Late 2024

Imbria's Ninerafaxstat Shows Safety Success in Phase 2 Heart Failure Study

Pharma, Clinical Trials, Latest News

Imbria Pharmaceuticals Clears Safety Hurdles in Phase 2 Heart Failure Trial, Paving the Way for Promising Late-Stage Development

Zimmer Biomet's Q3 Sales Growth and CEO Tornos' Vision for Innovation

Latest News, Pharma

Zimmer Biomet Sees Steady Q3 Sales Growth, New CEO Tornos Unveils Vision for an ‘Innovation Journey’

Pharmtales - your go-to source for comprehensive coverage of the pharmaceutical industry.

pharmtales
Latest Pharma News & Insights

© 2025 pharmtales.com | All rights reserved.

PRIVACY POLICY terms of service Contact us

Search for: